GlassScriptPhysician profile
James B Cooper
NPI 1639118482
$1,555.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $721 · 2021: $480 · 2022: $16.52 · 2024: $15.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $655.83 | 2019-2021 | |
| Genzyme Corporation | $202.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $175.75 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.61 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $113.55 | 2019-2021 | |
| Pfizer INC. | $95.48 | 2020-2021 | |
| Optinose US, INC. | $31.70 | 2019-2021 | |
| Mylan Specialty L.P. | $24.86 | 2020 | |
| Eyevance Pharmaceuticals LLC | $23.36 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.27 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $20.00 | 2021 | |
| Amgen INC. | $16.52 | 2022 | |
| Kaleo, INC. | $16.37 | 2021 | |
| Boston Scientific Corporation | $15.96 | 2024 | Lux-Dx Insertable Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.